< Back to previous page

Project

The SERENA study: Semaglutide for the treatment of glucose intolerance in women with prior gestational diabetes: a double blind RCT

The SERENA study (Semaglutide for the treatment of glucose intolerance in women with previous gestational diabetes: a double-blind RCT), is a collaboration with 12 centers (UZ Leuven, UZA, UZ Brussel, AZ Groeninge Kortrijk, AZ Delta Roeselare, Jessa hospital Hasselt , ZNA, OLV Aalst-Asse, AZ St Niklaas, Center Hospitalier Mouscron, CHU Liège and Erasme). The aim is to randomize about 206 women with prediabetes (based on the OGTT 6-24 weeks postpartum after a pregnancy with gestational diabetes) 1/1 to Ozempic (semaglutide) or placebo at a maximum of 1.5 years of age. The study is powered on the prevention of type 2 diabetes and the follow-up is up to 3 years. There is a study visit every 6 months (with alternating fasting 75g oral glucose tolerance test).

Date:30 Aug 2022 →  Today
Keywords:prevention, GLP-1 agonist, type 2 diabetes, Semaglutide, Glucose intolerance
Disciplines:Endocrinology
Project type:PhD project